Shopping Cart 0
Cart Subtotal
USD 0

Cancer Research Technology Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cancer Research Technology Ltd (CRT), formerly Cancer Research Campaign Technology Ltd, a subsidiary of Cancer Research UK, is a research organization that develops and commercializes discoveries for treatment in the areas of cancer. The organization offers services such as project development, drug discovery, commercialization, clinical development, imaging, and funding. It provides commercialization services to oncology institutes and also operates drug discovery laboratories. CRT serves pharmaceutical companies, clinical and academic institutions, and biotechnology companies. It provides online reagents research portal for the life science community. The organization operates in Massachusetts, the US and Cambridge, the UK. CRT is headquartered in London, the UK.

Cancer Research Technology Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deal Details 16

Venture Financing 16

GammaDelta Therapeutics Raises Funds through Seed Financing 16

ADC Therapeutics To Raise USD 50 Million In Venture Financing 17

Partnerships 19

Cancer Research Technology Enters into Partnership with Celgene 19

Cancer Research Technology Enters into Agreement with Merck 20

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 21

MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 22

Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 23

Artios Pharma Research Agreement with Cancer Research Technology 24

CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 25

Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 26

Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 27

Medivir Enters into Development Agreement with Cancer Research Technology 28

BioInvent And CRT Enter Into Research Agreement With University Of Southampton 29

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 30

Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 31

Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 33

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 34

HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 35

Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 36

Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 37

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 42

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 44

BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 46

Licensing Agreements 47

Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 48

Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 49

Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 50

Merck Enters into Licensing Agreement with Cancer Research Technology 51

Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 53

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 54

Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55

Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 56

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 57

BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 58

Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 59

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 60

Equity Offering 62

iOnctura Spin Out from Merck and Cancer Research Technology 62

Cancer Research Technology Ltd-Key Competitors 63

Cancer Research Technology Ltd-Key Employees 64

Cancer Research Technology Ltd-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Joint Venture 65

Recent Developments 67

Government and Public Interest 67

Jun 13, 2018: Cryo-EM reveals interaction between major drug targets 67

Apr 19, 2017: CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the 'undruggable' RAS 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cancer Research Technology Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

GammaDelta Therapeutics Raises Funds through Seed Financing 16

ADC Therapeutics To Raise USD 50 Million In Venture Financing 17

Cancer Research Technology Enters into Partnership with Celgene 19

Cancer Research Technology Enters into Agreement with Merck 20

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 21

MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 22

Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 23

Artios Pharma Research Agreement with Cancer Research Technology 24

CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 25

Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 26

Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 27

Medivir Enters into Development Agreement with Cancer Research Technology 28

BioInvent And CRT Enter Into Research Agreement With University Of Southampton 29

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 30

Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 31

Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 33

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 34

HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 35

Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 36

Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 37

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 42

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 44

BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 46

Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 48

Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 49

Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 50

Merck Enters into Licensing Agreement with Cancer Research Technology 51

Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 53

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 54

Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55

Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 56

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 57

BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 58

Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 59

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 60

iOnctura Spin Out from Merck and Cancer Research Technology 62

Cancer Research Technology Ltd, Key Competitors 63

Cancer Research Technology Ltd, Key Employees 64

Cancer Research Technology Ltd, Other Locations 65

Cancer Research Technology Ltd, Subsidiaries 65

Cancer Research Technology Ltd, Joint Venture 65

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cancer Research Technology Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cancer Research Technology Ltd (CRT), formerly Cancer Research Campaign Technology Ltd, a subsidiary of Cancer Research UK, is a research organization that develops and commercializes discoveries for treatment in the areas of cancer. The organization offers services such as project development, drug discovery, commercialization, clinical development, imaging, and funding. It provides commercialization services to oncology institutes and also operates drug discovery laboratories. CRT serves pharmaceutical companies, clinical and academic institutions, and biotechnology companies. It provides online reagents research portal for the life science community. The organization operates in Massachusetts, the US and Cambridge, the UK. CRT is headquartered in London, the UK.

Cancer Research Technology Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deal Details 16

Venture Financing 16

GammaDelta Therapeutics Raises Funds through Seed Financing 16

ADC Therapeutics To Raise USD 50 Million In Venture Financing 17

Partnerships 19

Cancer Research Technology Enters into Partnership with Celgene 19

Cancer Research Technology Enters into Agreement with Merck 20

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 21

MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 22

Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 23

Artios Pharma Research Agreement with Cancer Research Technology 24

CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 25

Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 26

Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 27

Medivir Enters into Development Agreement with Cancer Research Technology 28

BioInvent And CRT Enter Into Research Agreement With University Of Southampton 29

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 30

Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 31

Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 33

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 34

HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 35

Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 36

Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 37

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 42

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 44

BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 46

Licensing Agreements 47

Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 48

Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 49

Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 50

Merck Enters into Licensing Agreement with Cancer Research Technology 51

Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 53

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 54

Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55

Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 56

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 57

BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 58

Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 59

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 60

Equity Offering 62

iOnctura Spin Out from Merck and Cancer Research Technology 62

Cancer Research Technology Ltd-Key Competitors 63

Cancer Research Technology Ltd-Key Employees 64

Cancer Research Technology Ltd-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Joint Venture 65

Recent Developments 67

Government and Public Interest 67

Jun 13, 2018: Cryo-EM reveals interaction between major drug targets 67

Apr 19, 2017: CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the 'undruggable' RAS 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cancer Research Technology Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

GammaDelta Therapeutics Raises Funds through Seed Financing 16

ADC Therapeutics To Raise USD 50 Million In Venture Financing 17

Cancer Research Technology Enters into Partnership with Celgene 19

Cancer Research Technology Enters into Agreement with Merck 20

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 21

MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 22

Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 23

Artios Pharma Research Agreement with Cancer Research Technology 24

CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 25

Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 26

Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 27

Medivir Enters into Development Agreement with Cancer Research Technology 28

BioInvent And CRT Enter Into Research Agreement With University Of Southampton 29

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 30

Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 31

Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 33

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 34

HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 35

Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 36

Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 37

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 42

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 44

BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 46

Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 48

Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 49

Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 50

Merck Enters into Licensing Agreement with Cancer Research Technology 51

Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 53

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 54

Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55

Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 56

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 57

BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 58

Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 59

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 60

iOnctura Spin Out from Merck and Cancer Research Technology 62

Cancer Research Technology Ltd, Key Competitors 63

Cancer Research Technology Ltd, Key Employees 64

Cancer Research Technology Ltd, Other Locations 65

Cancer Research Technology Ltd, Subsidiaries 65

Cancer Research Technology Ltd, Joint Venture 65

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cancer Research Technology Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.